Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C

Vaccine

Volumn 28, Issue 7, 2010, Pages 1726-1731

  Chapko, Michael K ^a,b   Yee, Helen S ^c,d   Monto, Alexander ^c,d   Dominitz, Jason A ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Hepatitis C Resource Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Hepatitis A; Vaccine

Indexed keywords

HEPATITIS A VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH PROGRAM; HEPATITIS A; HEPATITIS C; HUMAN; IMMUNIZATION; MORBIDITY; PRIORITY JOURNAL; VACCINATION;

COST-BENEFIT ANALYSIS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS C, CHRONIC; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 75449083184     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.019     Document Type: Article

References (35)

1. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C infection in the United States, 1999 through 2002. Annals of Internal Medicine 144 (2006) 705-714
2. Dominitz J.A., Boyko E.J., Koepsell T.D., Heagerty P.J., Maynard C., Sporleder J.L., et al. Elevated prevalence of hepatitis C infection in users of United States Veterans Medical Centers. Hepatology 41 (2005) 88-96
3. Arguedas M.R., Heudebert G.R., Fallon M.B., and Stinnett A.A. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. American Journal of Gastroenterology 97 (2002) 721-728
4. Duncan M., Hirota W.K., and Tsuchida A. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. American Journal of Gastroenterology 97 (2002) 1792-1795
5. Jacobs R., and Meyeroff A. Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics. Sexually Transmitted Diseases 30 (2003) 859-865
6. Jacobs R.J., Koff R.S., and Meyeroff A.S. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. American Journal of Gastroenterology 97 (2002) 427-434
7. Jacobs R.J., Margolis H.S., and Coleman P.J. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Archives of Pediatrics and Adolescent Medicine 154 (2000) 763-770
8. Jacobs R.J., Saab S., Meyeroff A.S., and Koff R.S. An economic assessment of pre-vaccination screening for hepatitis A and B. Public Health Reports 118 (2003) 550-558
9. Jakiche R., Borrego M.E., Raisch D.W., Gupchup G.V., Pai M.A., and Jakiche A. The cost-effectiveness of two strategies for vaccinating U.S. veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses. The American Journal of the Medical Sciences 333 (2007) 26-34
10. Myers R.P., Gregor J.C., and Marotta P.J. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 31 (2000) 834-839
11. O'Connor J.B., Imperiale T.F., and Singer M.E. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatology 30 (1999) 1077-1081
12. Pechevis M., Khoshnood B., Durand I., Piquard Y., and Lafuma A. Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection. Vaccine 21 (2003) 3556-3564
13. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 37 (2003) 44-51
14. Saab S., Martin P., and Yee H. A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination. The American Journal of Medicine 109 (2000) 241-244
15. Siddiqui F., Mutchnick M., Kinzie J., Peleman R., Naylor P., and Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. American Journal of Gastroenterology 96 (2001) 858-863
16. Tormans G., Van Damme P., and Van Doorslaer E. Cost-effectiveness analysis of hepatitis A prevention in travelers. Vaccine 10 Suppl 1 (1992) S88-S92
17. Koff R.S. Risks associated with hepatitis A and hepatitis B with hepatitis C. Journal of Clinical Gastroenterology 33 (2001) 20-26
18. Shim M., Khaykis I., Park J., and Bini E.J. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 42 (2005) 688-695
19. Modlin J. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48 RR-12 (1999) 1-37
20. Keifer L.A., Honish A., Predy G., and Talbot J.A. The seroprevalence of hepatitis A and B in people testing positive for hepatitis C. Canadian Medical Association Journal 162 (2000) 207-208
21. Meyer J.M. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. The Journal of Clinical Psychiatry 64 (2003) 540-545
22. Saab S., Lee C., Shpaner A., and Ibrahim A.B. Seroepidemiology of hepatitis A in patients with chronic liver disease. Hepatology 12 (2005) 101-105
23. Suharto T., and Jacobson I. Prevalence of hepatitis A antibodies in HCV-infected persons in New York City. American Journal of Gastroenterology 93 (1998) 1680
24. Jakiche R., Dwivedi P., Borrego M., Raisch D., Gupchup G., Pai M., et al. US Veterans with hepatitis C have a high prevalence of immunity to hepatitis A and hepatitis B, and a high prevalence of decompensated liver disease. American Journal of Gastroenterology 99 Suppl (2004) S84-S85
25. Wasley A., Grytdal S., and Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveillance Summaries 57 SS-2 (2008) 1-24
26. Wasley A., Miller J., and Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveillance Summaries 56 SS-3 (2007) 1-24
27. Laupacis A., Feeny D., Detsky A., and Tugwell P. Tentative guidelines for using clinical and economic evaluations revisited. Canadian Medical Association Journal 148 6 (1993) 927-929
28. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 146 (1992) 927-929
29. Ubel P., Hirth R., Chernew M., and Fendrick A. What is the price of life and why doesn't it increase at the rate of inflation?. Archives of Internal Medicine 163 (2005) 1637-1641
30. Vogt T., Wise M., Bell B., and Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. Journal of Infectious Diseases 197 9 (2008) 1282-1288
31. Deneke M.G., and Arguedas M.R. Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs. Expert Review of Vaccines 2 (2003) 661-672
32. Arguedas M.R., Johnson A., Eloubeidi M.A., and Fallon M.B. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. American Journal of Gastroenterology 34 (2001) 28-31
33. Younossi Z., Boparai N., McCormick M., Price L.L., and Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. American Journal of Gastroenterology 96 (2001) 579-583
34. Younossi Z., Singer M.E., McHutchinson J., and Shermock K.M. Cost effectiveness of interferon a2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30 (1999) 1318-1324
35. Arias E. United States life tables, 2002. National Vital Statistics Reports 53 6 (2004)